Erratum to: “Biotechnological Method for Production of Recombinant Peptide Analgesic (Purotoxin-1) from Geolycosa sp. Spider Poison”

Resumo

Page 37, left column, last sentence should read:

The concentration of the recombinant PT1 preparation, which causes 50% inhibition of the currents mediated by P2X3 receptors in the rate-sensor neurons (IC₅₀), was 12 ± 2 nM at Hill coefficient (n_H) 1.1 ± 0.2 (for RO-85 IC₅₀ relative to recombinant rat receptors was ~31 nM) [15].

Section REFRENCES, add reference:

15. Esipov, R.S., Stepanenko, V.N., Vasilevskii, A.A., Korol’kova, Yu.V., and Grishin, E.V., Method for obtaining recombinant analgesic peptide, RF Patent no. 2571942, Byul. Izobret., 2015, no. 36.

Add section ACKNOWLEDGMENTS:

The works comparing recombinant and natural PT1 were carried out by A.A. Vasilevskii (Institute of Bioorganic Chemistry, Russian Academy of Sciences), G.A. Savchenko and O.A. Kryshtal’ (Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine).

This work was supported by the State Contract dated June 14, 2012, No. 16.N08.12.1023 “Preclinical Studies on Polypeptide Analgesic Selectively Interacting with Purinergic Receptors”.

The original article can be found online at DOI: 10.1134/S1068162018010065.